Tuesday, November 6, 2012

Manage Estrogen to Raise Testosterone. SERMs: Anti-Estrogen and Anti-Aromatase Products

Aromatase is an enzyme which converts testosterone to estrogen. Inhibiting aromatase increases testosterone and reduces estrogen, promoting muscle growth and fat loss. Numerous studies have seem to have confirmed this.

In this post I will look at a few of the current means of estrogen management. Often referred to as SERMs or Selective Estrogen Receptor Modulators.

Before with get to the current popular ingredients, let's talk about lifestyle things you can do. These are especially important if you belong to the "big belly club" like me.

  • Lift heavy to build more muscle and burn more glycogen. Less glycogen stores means more body fat burned. 
  • Avoid soy, wheat and flax. Yeah, I know, it's probably bro science but why take a chance. Especially if you are already estrogen prone. 
  • Get 8 hours of sleep. 
  • Avoid alcohol. 
  • Get some. If you don't know what some is.....you already may have lost the fight. 
  • Avoid plastic containers. Water bottles and heating food in plastics. BPA has estrogenic effects. 
  • Eat proteins and don't be afraid of saturated fats. Whole eggs. At least 1 gram per pound of lean body weight. If you weight 200 pounds but you are 30% body fat, don't eat 200 grams of protein. Your lean mass is closer to 140 to 150 pounds lean. About 20 to 30% of your calories should come from fat. 
  • Eat 2 grams of carbs per pound of body weight or less. Learn your body. I'm king endomorph I need to eat less. Most dudes can eat a 2 to 1 ratio of carbs to protein. 
  • If you are a lean dude. No belly and no moobs. Don't worry about estrogen.
  • Eat broccoli and other cruciferous vegetables such as cauliflower and cabbage. They are powerful estradiol blockers.
Now to the individual supplements.

The old standbys:


In healthy young men, it cuts "bad" estrogens in half by helping the liver neutralize them. DIM doesn't actually reduce estrogens. What is does is help the liver convert them into weaker forms.

Take 200-300 mg as 2-3 divided doses.


Calcium D-glucarate attaches itself to estrogens in your intestines and passes them out into your toilet bowl. Otherwise, your body's could reabsorb a significant out of estrogens your body intends to eliminate. The only possible downside is that it also helps remove excess testosterone and cortisol, but only the overspill that's already destined for elimination. Take 800-600 mg as 2-8 divided doses.

Damiana Extract

University of Mississippi (Oxford) researchers discovered that damiana leaf extract inhibits the aromatase enzyme that converts testosterone into estrogen in the body. Take 50-500 milligrams three times per day between meals.


5, 7-dihydroxyflavone or chrysin is a flavonoid compound found in many plants and in honey. It has been known for years to inhibit the aromatase enzyme and block the conversion of testosterone into estrogen. Recent research from Texas Tech University (Lubbock) finds that it can also directly increase testosterone production. Take 1 gram of chrysin with breakfast, lunch and dinner.


Is an anti-estrogen supplement. It lowers estrogen promoting higher testosterone levels. It also has been found to enhance protein synthesis and lower cortisol levels. Take 500-2,000mg per day in three divided doses with meals

Indole-3-carbinol (I3C)

A closely related derivative diindolylmethane (DIM), naturally occurring phytochemicals also reduces the strength of estrogens by converting them to weaker varieties in the liver.

The new entry's (most are natural ingredients that bind to estrogen receptors):


Known as the ingredient from the French paradox, resveratrol is a SERM type product that has many other health promoting benefits. Resveratrol has been shown in studies to not only block estrogen but and increase LH leading to higher testosterone levels.

Ellagic Acid

This is typically an extract of raspberries and pomegranate. It has been studied to block estrogen.


This is the soy paradox. We typically say don't take soy. Daidzein which is a metabolite of soy that has weak estrogenic activity.

Grape Seed Extract.

Many studies have shown Grape Seed Extract to be a good aromatase inhibitor.

This poly phenol found in the skin of apples has been shown to increase muscle growth and strength by increasing production of IGF-1 and reducing the amount of testosterone that gets converted to estrogen. It has also been shown to increase fat loss while simultaneously building more muscle. Take 250-l,500mg 30-60 minutes before workouts.

Ipriflavone or 7-hydroxyflavone

Doses equivalent to about 500 mg for humans, easily reachable with lpriflavone supplements. Studies have found that serum testosterone levels increased, estrogen levels decreased, and muscle RNA went up 5%-10% (meaning more muscle protein was being directed) due to aromatase inhibition.

Stinging nettle

Ori Hofmekler (The Warrior Diet) lists this as having anti-aromatase agent. I will have to do further research.

Safflower Seed

Carthamus tinctorius (Compositae) as an anti-estrogenic. Studies have shown that tracheloside significantly decreased the activity of alkaline phosphatase (AP), an estrogen-inducible marker enzyme. As such CLA has also been pro ported to have anti-estrogenic capabilities.


Chaste tree or Vitex agnus castus contains the active compounds known as agnosides that work to reduce estrogen levels and boost luteinizing hormone (LH) levels. In males, this can lead to a dramatic increase in testosterone. Take 200-400 mg of vitex agnus castus or chasteberry extract immediately before bed. Take it in 6-8-week cycles, then lay off for about four weeks before starting the next cycle.

Citrus Bioflavonoids

Hesperetin is created by metabolising hesperidin in the stomach which is found in citrus fruits, especially orange. Naringenin is another citrus bioflavonoid whose metabolites are able to lower aromatase enzyme and estrogen. They do this by attaching to receptor sites.

Bee Propolis

Has been shown to be effective in the fight against xenoestrogens.

Vitamin D

Has been shown to be a natural aromatase inhibitor.


Has promise as an aromatase inhibitor by occupying estrogen receptors. 


Previous Posts:

Cutting Stack: BPI Sports A-HD and Solid

Contest Drawing: Enter to Win BPI Sports A50 and A-HD Stack. Get a headstart on your mass stack.


Damiana + chrysin: stack these two aminos to send nitric oxide levels skyrocketing.  Jim Stoppani.
Flex. 27.9 (Nov. 2009): p132.

"Grow your chest, not your breasts." Men's Fitness July 2002: 66+.

Your T, on E. Murphy, Myatt. Men's Health, Sep2012, Vol. 27 Issue 7, p86-87, 2p

ERADICATE ESTROGEN TO FUEL YOUR GROWTH. Rowley, Brian. Stoppani, Jim. Joe Weider's Muscle & Fitness, Oct2003, Vol. 64 Issue 10, p176

ESTROGEN NATION. Lockwood, Chris. Joe Weider's Muscle & Fitness, Nov2009, Vol. 70 Issue 11, p94-97

Araujo, A., Chiu, G., Kupelian, V., Rosen, R., & McKinlay, J. (2010, May 29). Relative contributions of modifiable risk factors to erectile dysfunction [Abstract 17]. Journal of Urology, 183(Suppl. 4), e7-e8.
Araujo, A., Durante, R., Feldman, H. A., Goldstein, I., & McKinlay, J. B. (1998). The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosomatic Medicine, 60, 458-465.
Azadzoi, K. M., & Saenz de Tejada, I. (1991). Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. Journal of Urology, 146, 238-240.
Bacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003). Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Annals of Internal Medicine, 139, 161-168.
Buvat, J., Montorsi, F., Maggi, M., Porst, H., Kaipia, A., Colson, M. H., et al. (2011). Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST Study). Journal of Sexual Medicine, 8, 284-293.
Caminiti, G., Volterrani, M., & Iellamo, F. (2009). Effect of longacting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. Journal of the American College of Cardiology, 54, 919-927.

Cheng, J. Y., & Ng, E. M. (2007). Body mass index, physical activity and erectile dysfunction: A U-shaped relationship from a populationbased study. International Journal of Obesity, 31, 1571-1578.
Corona, G., Mannucci, E., Lotti, F., Boddi, V., Jannini, E. A., Fisher, A. D., et al. (2009). Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. Journal of Sexual Medicine, 6, 2591-600.
Corona, G., Mannucci, E., Schulman, C., Petrone, L., Mansani, R., Cilotti, A., et al. (2006). Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. European Urology, 50, 595-604.
Corona, G., Monami, M., Boddi, V., Balzi, D., Melani, C., Federico, N., et al. (2010). Is obesity a further cardiovascular risk factor in patients with erectile dysfunction? Journal of Sexual Medicine, 7, 2538-2546.
Daubenmier, J. J., Weidner, G., Marlin, R., Crutchfield, L., Dunn-Emke, S., Chi, C., et al. (2006). Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology, 67, 125-130.
Davidson, J. M., Chen, J. J., Crapo, L., Gray, G. D., Greenleaf, W. J., & Catania, J. A. (1983). Hormonal changes and sexual function in aging men. Journal of Clinical Endocrinology and Metabolism, 57, 71-77.
De Boer, B. J., Bots, M. L., Lycklama a Nijeholt, A. A., Moors, J. P., Pieters, H. M., & Verheij, T. J. (2004). Erectile dysfunction in primary care: Prevalence and patient characteristics. The ENIGMA study. International Journal of lmpotence Research, 16, 358-364.
Derogatis, L. R., & Burnett, A. L. (2008). The epidemiology of sexual dysfunctions. Journal of Sexual Medicine, 5, 289-300.
Dod, H. S., Bhardwaj, R., Sajja, V., Weidner, G., Hobbs, G. R., Konat, G. W., et al. (2010). Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. American Journal of Cardiology, 105, 362-367.
Duncan, B. B., & Schmidt, M. I. (2001). Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Medical Journal, 119, 122-127.
Dunn-Emke, S., Weidner, G., Pettengill, E., Marlin, R. O., Chi, C., & Ornish, D. (2005). Nutritional adequacy of a very low-fat vegan diet. Journal of the American Dietetic Association, 105, 1442-1446.
Esposito, K., Giugliano, F., DiPalo, C., Giugliano, G., Marfella, R., D'Andrea, F., et al. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. Journal of the American Medical Association, 291, 2978-2984.
Esposito, K., Giugliano, F., Maiorino, M. I., & Giugliano, D. (2010). Dietary factors, Mediterranean diet and erectile dysfunction. Journal of Sexual Medicine, 7, 2338-2345.
Everitt, B. J. (1995). Neuroendocrine mechanisms underlying appetitive and consummatory elements of masculine sexual behaviour. In J. Bancroft (Ed.), The pharmacology of sexual function and dysfunction (pp. 15-31). Amsterdam, the Netherlands: Excerpta Medica.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001).

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J.,& McKinlay, J. B. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. Journal of Urology, 151, 54-61.
Feldman, H. A., Johannes, C. B., Derby, C. A., Kleinman, K. P., Mohr, B. A., Araujo, A. B., et al. (2000). Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Preventive Medicine, 30, 328-338.
Giltay, E. J., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J., Saad, F., & Kalinchenko, S. Y. (2010). Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Journal of Sexual Medicine, 7, 2572-2582.
Gluckman, P. D., & Hanson, M. A. (2004). The developmental origins of the metabolic syndrome. Trends in Endocrinology and Metabolism, 15, 183-187.
Gooren, L. J. G. (1987). Androgen levels and sex functions in testosterone-treated hypogonadal men. Archives of Sexual Behavior, 16, 463-473.
Gray, A., Feldman, H. A., McKinlay, J. B., & Longcope, C. (1991). Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. Journal of Clinical Endocrinology and Metabolism, 73, 1016-1025.
Hannan, J. L., Maio, M. T., Komolova, M., & Adams, M. A. (2009). Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. Journal of Sexual Medicine, 6(Suppl. 3), 254-261.
Heinemann, L. A., Zimmermann, T., Vermeulen, A., & Thiel, C. (1999). A new "Aging Male's Symptoms" (AMS) Rating Scale. Aging Male, 2, 105-114.
Isidori, A. M., Caprio, M., Strollo, F., Moretti, C., Frajese, G., Isidori, A., et al. (1999). Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. Journal of Clinical Endocrinology and Metabolism, 84, 3673-3680.
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E. J., Moncada, I., et al. (2010). Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome: The TIMES2 Study. Diabetes Care. Manuscript submitted for publication.
Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J., Giltay, E. J., & Saad, F. (2010). Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clinical Endocrinology, 73, 602-612.
Kalyani, R. R., & Dobs, A. S. (2007). Androgen deficiency, diabetes, and the metabolic syndrome in men. Current Opinion in Endocrinology, Diabetes and Obesity, 14, 226-234.
Kaukua, J., Pekkarinen, T., Sane, T., & Mustajoki, P. (2003). Sex hormones and sexual function in obese men losing weight. Obesity Research, 11, 689-694.
Khaw, K. T., Dowsett, M., & Folkerd, E. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 116, 2694-2701.
Kim, J. H., Klyachkin, M. L., Svendsen, E., Davies, M. G., Hagen, P. O., & Carson, C. C., III. (1994). Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. Journal of Urology, 151, 198-205.
Koncz, L., & Balodimos, M. C. (1970). Impotence in diabetes mellitus. Medical Times', 98, 159-170.
Kratzik, C. W., Lackner, J. E., Mark, I., Rticklinger, E., Schmidbauer, J., Lunglmayr, G., et al. (2009). How much physical activity is needed to maintain erectile function? Results of the Androx Vienna Municipality Study. European Urology, 55, 509-516.
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssonen, K., Tuomainen, T. P., & Salonen, R. (2003). Sex hormones, inflammation, and the metabolic syndrome: A population-based study. European Journal of Endocrinology, 149, 601-608.
Larsen, S. H., Wagner, G., & Heitmann, B. L. (2007). Sexual function and obesity. International Journal of Obesity, 31, 1189-1198.
Leenen, R., van der Kooy, K., Seidell, J. C., Deurenberg, P.,& Koppeschaar, H. P. (1994). Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. Journal of Clinical Endocrinology and Metabolism, 78, 1515-1520.
Legros, J. J., Meuleman, E. J., Elbers, J. M., Geurts, T. B., Kaspers, M. J., & Bouloux, P. M. (2009). Oral testosterone replacement in symptomatic late-onset hypogonadism: Effects on rating scales and general safety in a randomized, placebo-controlled study. European Journal of Endocrinology, 160, 821-831.
Lehman, T. P., & Jacobs, J. A. (1983). Etiology of diabetic impotence. Journal of Urology, 129, 291-294.
Lewis, R. W., Fugl-Meyer, K. S., Corona, G., Hayes, R. D., Laumann, E. O., Moreira, E. D. Jr., et al. (2010). Definitions/epidemiology/ risk factors for sexual dysfunction. Journal of Sexual Medicine, 7, 1598-1607.
Lindau, S. T., & Gavrilova, N. (2010). Sex, health, and years of sexually active life gained due to good health: Evidence from two US population-based cross sectional surveys of ageing. British Medical Journal, 340, c810.
Maggio, M., Lauretani, F., Ceda, G. P., Bandinelli, S., Ling, S. M., Metter, J., et al. (2007). Relationship between low levels of anabolic hormones and 6-year mortality in older men: The aging in the Chianti Area (InCHIANTI) study. Archives of Internal Medicine, 167, 2249-2254.
McNamara, E. R., Alfred-Thomas, J. A., & Freedland, S. J. (2010, June 1). Exercise correlates to higher sexual function scores in a cohort of healthy men [Abstract 1500]. Journal of Urology, 183(Suppl. 4), e578.
Meinhardt, W., Kropman, R. F., Vermeij, P., Nijeholt, A. A. B.,& Zwartendijk, J. (1997). The influence of medication on erectile function. International Journal of Impotence Research, 9, 17-26.
Meuleman, E. J., Donkers, L. H., Robertson, C., Keech, M., Boyle, P., & Kiemeney, L. A. (2001). Erectile dysfunction: Prevalence and effect on the quality of life; Boxmeer study. Nederlands Tijdschrift voor Geneeskunde, 145, 576-581.
Meuleman, E. J., & van Lankveld, J. J. (2005). Hypoactive sexual desire disorder: An underestimated condition in men. British Journal of Urology International, 95, 291-296.
Mooradian, A. D., Morley, J. E., & Korenman, S. G. (1987). Biological actions of androgens. Endocrine Reviews, 8, 1-28.
Nelson, R. J. (2000). An introduction to behavioral endocrinology (2nd ed.). Sunderland, MA: Sinauer.
Nieschlag, E. (1979). The endocrine function of the human testis in regard to sexuality. In Ciba Foundation Symposium 62--Sex, hormones and behaviour (pp. 182-208). Amsterdam, the Netherlands: Excerpta Medica.
Okabe, H., Hale, T. M., Kumon, H., Heaton, J. P., & Adams, M. A. (1999). The penis is not protected--In hypertension there are vascular changes in the penis which are similar to those in other vascular beds. International Journal of Impotence Research, 11, 133-140.
Ornish, D., Brown, S. E., Scherwitz, L. W., Billings, J. H., Armstrong, W. T., Ports, T. A., et al. (1990). Can lifestyle changes reverse coronary heart disease?: The Lifestyle Heart Trial. Lancet, 336, 129-133.
Park, M. G., Oh, M. M., Lee, D. S., Yu, J. W., & Bae, J. H. (2010, June 1). The characteristics and predictive factors of nonresponders to testosterone replacement therapy in testosterone deficiency syndrome [Abstract 1381]. Journal of Urology, 183(Suppl. 4), e533-e534.
Prins, J., Blanker, M. H., Bohnen, A. M., Thomas, S., & Bosch, J. L. (2002). Prevalence of erectile dysfunction: a systematic review of population-based studies. International Journal of Impotence Research, 14, 422-432.
Rask, E., Olsson, T., Soderberg, S., Andrew, R., Livingstone, D. E., Johnson, O., et al. (2001). Tissue-specific dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism, 86, 1418-1421.
Reaven, G. M. (1988). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
Rizvi, S. J., Kennedy, S. H., Ravindran, L. N., Giacobbe, P., Eisfeld, B. S., Mancini, D., et al. (2010). The relationship between testosterone and sexual function in depressed and healthy men. Journal of Sexual Medicine, 7, 816-825.
Rodriguez, A., Muller, D. C., Metter, E. J., Maggio, M., Harman, S. M., Blackman, M. R., et al. (2007). Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. Journal of Clinical Endocrinology and Metabolism, 92, 3568-3572.
Rosen, R. C., Friedman, M., & Kostis, J. B. (2005). Lifestyle management of erectile dysfunction: The role of cardiovascular and concomitant risk factors. American Journal of Cardiology, 96, 76M-79M.
Rosmond, R., Wallerius, S., Wanger, P., Martin, L., Holm, G.,& Bjorntorp, P. (2003). A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. Journal of Internal Medicine, 254, 386-390.
Saltzman, E. A., Guay, A. T., & Jacobson, J. (2004). Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: A clinical observation. Journal of Urology, 172, 255-258.
Saylor, P. J., & Smith, M. R. (2009). Metabolic complications of androgen deprivation therapy for prostate cancer. Journal of Urology, 181, 1998-2008.
Schouten, B. W., Bohnen, A. M., Dohle, G. R., Groeneveld, F. P., Willemsen, S., Thomas, S., et al. (2009). Risk factors for deterioration of erectile function: The Krimpen study. International Journal of Andrology, 32, 166-175.
Schroeder, E. T., Zheng, L., Ong, M. D., Martinez, C., Flores, C., Stewart, Y. R., et al. (2004). Effects of androgen therapy on adipose tissue and metabolism in older men. Journal of Clinical Endocrinology and Metabolism, 89, 4863-4872.
Seidell, J. C., Bjorntorp, P., Sjostrom, L., Kvist, H., & Sannerstedt, R. (1990). Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels but negatively with testosterone levels. Metabolism, 39, 897-901.
Shabsigh, R., Kaufman, J. M., Steidle, C., & Padma-Nathan, H. (2004). Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. Journal of Urology, 172, 658-663.
Shiri, R., Koskimaki, J., Hakkinen, J., Auvinen, A., Tammela, T. L., & Hakama, M. (2007). Cardiovascular drug use and the incidence of erectile dysfunction. International Journal of Impotence Research, 9, 208-212.
Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006). Low serum testosterone and mortality in male veterans. Archives of Internal Medicine, 166, 1660-1665.
Simons, L. P. A., & Hampe, J. F. (2010, June). Service experience design for healthy living support: Comparing an in-house with an eHealth solution. Paper presented at the 23rd Bled eConference eTrust on Implications for the Individual, Enterprises and Society, Bled, Slovenia.
Speel, T. G., Kiemeney, L. A., Thien, T., Smits, P., & Meuleman, E. J. (2005). Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: A pilot study. Journal of Sexual Medicine, 2, 207-212.
Stull, V. B., Snyder, D. C., & Demark-Wahnefried, W. (2007). Lifestyle interventions in cancer survivors: Designing programs that meet the needs of this vulnerable and growing population. Journal of Nutrition, 137(Suppl. 1), 243S-248S.
Stulnig, T. M., & Waldhausl, W. (2004). 11beta-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia, 47, 1-11.
Traish, A. M. (2009). Androgens play a pivotal role in maintaining penile tissue architecture and erection: A review. Journal of Andrology, 30, 363-369.
Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology, 30, 10-22.
Traish, A. M., Saad, F., Feeley, R. J., & Guay, A. (2009). The dark side of testosterone deficiency: III. Cardiovascular disease. Journal of Andrology, 30, 477-494.
Walker, B. R. (2001). Steroid metabolism in metabolic syndrome X. Best Practice & Research in Clinical Endocrinology and Metabolism, 15, 111-122.
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H., Hellstrom, W. J., Gooren, L. J., et al. (2009). ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male, 12, 5-12.
White, J. R., Case, D. A., McWhirter, D., & Mattison, A. M. (1990). Enhanced sexual behavior in exercising men. Archives of Sexual Behavior, 19, 193-209.
Wild, S. H., & Byrne, C. D. (2006). The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In C. D. Byrne & S. H. Wild (Eds.), The metabolic syndrome (pp. 1-33). Weinheim, Germany: Wiley.
You, D., Ji, Y. I., Moon, K., Hong, J. H., & Ahn, T. H.0 (2010, May 31). The association of the metabolic syndrome and its components with the serum testosterone level: Results of a large volume screened population cohort [Abstract 707]. Journal of Urology, 183(Suppl. 4), e276.
Zitzmann, M., Faber, S., & Nieschlag, E. (2006). Association of specific symptoms and metabolic risks with serum testosterone in older men. Journal of Clinical Endocrinology and Metabolism, 91, 4335-4343.